Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA topoisomerase-DNA cleavage complex is a transient, covalent intermediate formed during the catalytic cycle of topoisomerase enzymes as they resolve topological strain in DNA (Pommier, 2013). These enzymes are essential for processes such as DNA replication, transcription, and chromosome segregation by creating temporary single- or double-strand breaks (Nitiss, 2009). In the context of oncology, this complex is the specific target of topoisomerase poisons, which trap the enzyme on the DNA, preventing the religation of the phosphodiester backbone (StatPearls, 2023). When the replication machinery or RNA polymerase encounters these stabilized complexes, it leads to the formation of permanent, lethal DNA double-strand breaks (Pommier, 2013). Tumor cells are often more susceptible to this damage due to their rapid proliferation rates and potential defects in DNA repair pathways (NIH, 2022). Consequently, targeting this complex remains a cornerstone of chemotherapy for various solid tumors and hematological malignancies (Nitiss, 2009). The stabilization of this complex is distinct from catalytic inhibition, as it converts an essential enzyme into a cellular toxin (Pommier, 2013). Clinical efficacy is often limited by the development of resistance mechanisms, such as the upregulation of repair enzymes like tyrosyl-DNA phosphodiesterase 1 (Delgado et al., 2018).
Stabilization of the transient covalent intermediate formed between topoisomerase enzymes and DNA, preventing the religation of DNA strands and leading to lethal double-strand breaks during replication (Pommier, 2013; StatPearls, 2023).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase-DNA cleavage complex (Topo-DNA CC) (Topo-DNA CC).